TrialNature communications2025

Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006).

Xiaohui Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.